Eyeing the EfficacyThere's more supportive efficacy data on slides 20 and 21: A response rate for STA-4783 of 15.1% compared to 3.6% for the control arm. This is the percent of patients in each arm of the study who saw their tumors shrink by at least 50%. STA-4783 patients also reported a median overall survival of 12 months compared to 7.8 months for the control-arm patients. Neither of these results is statistically significant, which isn't ideal but also unsurprising given the number of patients enrolled in the study. From all this data, you can see why a randomized, controlled study is important and a nice thing to have -- the control arm provides a tangible yardstick by which the drug's efficacy can be measured. For cancer drugs, efficacy reigns supreme, but safety is an important consideration, too. In this case, STA-4783's toxicity profile, outlined in slides 27-29, doesn't look out of the ordinary. At this point, you could stop your research and say reasonably that Synta has put together some compelling data on STA-4783 as a potential melanoma drug; at least enough data that would pique my interest as a biotech investor.